Could CBD Help Fight Atherosclerosis?

Atherosclerosis is often described as a cholesterol problem, but the biology behind clogged arteries is far more complicated. Inflammation, oxidative stress, endothelial dysfunction, immune activity, and changes in lipid metabolism can all contribute to the formation and progression of arterial plaque.

That complexity has researchers looking beyond traditional cholesterol-lowering strategies, and one compound attracting attention is cannabidiol, better known as CBD. A newly published preclinical study¹ has raised an intriguing question: Could CBD influence atherosclerosis without actually lowering cholesterol? The answer from the research is interesting but not yet be the green light for using CBD to prevent heart disease as researchers may have hoped. Let’s dive into the study and what it means for the future of pharmaceutical-grade CBD.

CBD and Cardiovascular Health

CBD is a non-intoxicating cannabinoid found predominantly in hemp. Previous research has explored its potential effects on inflammation and oxidative stress, two processes that are also closely connected to cardiovascular disease.

Oxidative stress occurs when the production of reactive molecules overwhelms the body’s ability to neutralize them. Within blood vessels, excessive oxidative stress can contribute to endothelial dysfunction and inflammatory signaling. These processes can help create an environment in which atherosclerotic plaques develop.

The study, published in the Journal of Lipid Research, investigated whether CBD could affect plaque development in a mouse model specifically prone to atherosclerosis. However, the most interesting part of the research was not simply whether CBD affected plaque, but who appeared to benefit.

What the CBD Study Found

Researchers used male and female apolipoprotein E-deficient, or ApoE−/−, mice. These animals were fed a Western-type diet for 12 weeks to promote atherosclerosis. The mice received either CBD in a nanoemulsion or a vehicle control through their drinking water. The CBD exposure was approximately 80 mg/kg per day.

There were only eight mice in each treatment group, making this a small preclinical experiment rather than evidence that could be directly translated to humans. When researchers examined the aortas, they found a significant reduction in plaque area among the CBD-treated male mice. The female mice, however, told a very different story, as CBD did not significantly reduce plaque formation in females. This sex difference is one of the most important findings because it suggests that CBD’s potential cardiovascular effects may not be universal.

CBD Did Not Lower Cholesterol

Perhaps one of the most surprising findings was what did not change. CBD did not significantly alter conventional serum lipid measurements, including total cholesterol, LDL cholesterol, HDL cholesterol, or triglycerides. Body weight was also unaffected.

That means the reduction in plaque observed in male mice cannot simply be explained by CBD acting like a conventional cholesterol-lowering therapy. Instead, researchers found evidence pointing toward another possibility: that vascular inflammation and oxidative stress may be more important to CBD’s effects than traditional cholesterol reduction.

This distinction matters, because atherosclerosis is not caused by cholesterol alone. LDL particles can become modified or oxidized, triggering inflammatory responses within the arterial wall. Endothelial cells lining blood vessels can also become activated under conditions of oxidative stress, contributing to the development of plaque. The researchers therefore investigated whether CBD might be influencing these processes directly.

CBD May Affect Vascular Oxidative Stress

The study’s molecular findings provided some clues. In male mice, CBD was associated with changes in proteins involved in mitochondrial activity and oxidative stress. Several mitochondrial pathways, including aerobic respiration and respiratory electron transport, were downregulated following CBD treatment.

The researchers also tested CBD in human coronary artery endothelial cells exposed to oxidized LDL, a laboratory model designed to reproduce some of the inflammatory and oxidative conditions involved in early atherosclerosis. Under those conditions, CBD reduced markers of oxidative stress, decreased inflammatory activation, and reduced expression of the endothelial adhesion molecule ICAM.

Together, these findings support a possible vascular mechanism: rather than simply changing how much cholesterol is circulating in the blood, CBD may influence how blood-vessel cells respond to oxidative and inflammatory stress. However, that mechanism remains a hypothesis requiring much more research.

Why the Lipid Findings Matter

The researchers also performed detailed lipidomic analysis, examining hundreds of individual lipid molecules rather than relying only on standard cholesterol and triglyceride measurements. They found the global lipidome was not dramatically changed by CBD. However, male mice showed changes in specific lipid species, particularly ether-linked triacylglycerols. These molecules belong to a broader group of ether lipids involved in cellular metabolism and, potentially, redox biology.

Some ether-linked lipid species were associated with lower plaque burden in the male mice and were also increased following CBD treatment. However, the researchers were careful not to claim that these lipids caused the reduction in plaque. Their analysis did not establish a causal mediation pathway. The findings are best viewed as clues for future research, not proof of a mechanism.

Why Male and Female Results Differ

The lack of an effect in female mice may ultimately prove just as important as the positive result in males. Cannabinoids can interact with numerous biological pathways, and responses can vary according to hormones, metabolism, receptor expression, and pharmacokinetics. Sex-specific responses have been observed in other areas of cannabinoid research, but cardiovascular effects have received considerably less attention.

This study highlights why researchers cannot assume that a finding observed in male animals will automatically apply to females. In this case, CBD produced measurable plaque and molecular changes in males while producing no comparable plaque or major proteomic effects in females. That is a major limitation, and an important scientific finding at the same time.

The CBD Dose Raises Questions

Another critical consideration is the CBD dose. The mice received approximately 80 mg/kg/day of nanoemulsified CBD. That’s a high experimental exposure and involved a specific nanoemulsion formulation designed to improve CBD delivery.

Consumers do not necessarily absorb CBD from conventional oils, capsules, beverages, or other products in the same way. This is because CBD has relatively low and variable oral bioavailability. The study therefore cannot be used to conclude that an ordinary over-the-counter CBD product would produce the same biological effects.

What This Means for Heart Disease

The findings are promising enough to warrant further investigation, but they should not be mistaken for evidence that CBD prevents cardiovascular disease. This study involved mice, used a very small sample of only eight mice per treatment group, and a high experimental dose of nanoemulsified CBD. Most importantly, the apparent reduction in plaque occurred in males and was not observed in female animals. There is therefore no basis from this study to recommend consumer CBD as an intervention for atherosclerosis or to suggest that CBD can replace established cardiovascular treatments.

However, the research does provide a fascinating new direction. If future studies confirm the findings, CBD could potentially become part of a broader investigation into how cannabinoids influence vascular oxidative stress, endothelial inflammation, and lipid metabolism.

CBD and Atherosclerosis: What’s Next?

The next step is determining whether these observations can be reproduced in larger animal studies and, eventually, whether anything similar occurs in humans. Researchers will also need to determine whether different CBD formulations produce different effects, what doses are biologically meaningful, why males and females respond differently, and whether the changes in mitochondrial and lipid metabolism actually contribute to plaque reduction. Human studies will be particularly important because CBD’s absorption, metabolism and cardiovascular effects can differ substantially between humans and laboratory animals.

For now, the most accurate takeaway is not that CBD fights heart disease, but that researchers have identified a potentially important pathway worth investigating for potential therapeutic applications in the future.

References:

^{1. Cahova M, Ableitner E, Bechyňská K, Kučková Š, Viktorova J, Mikušová V, Kosek V, Bínová Z, Beneš F, Fabián O, Strnad O, Nejedlý T, Heczková M, Brátová M, Kaštánek P, Malý M, Hajšlová J, Mussbacher M, Stranska M, Cannabidiol attenuates atherosclerosis in male ApoE−/− mice with sex-dependent lipidomic and proteomic remodeling, Journal of Lipid Research (2026), doi: https://doi.org/10.1016/j.jlr.2026.101120}